Claims for Patent: 9,119,854

Summary for Patent: 9,119,854

Title:	Methods for treating cancer using combination therapy
Abstract:	Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a substituted quinazolinone compound and an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phen- yl)acrylamide to a patient having a cancer.
Inventor(s):	Chopra; Rajesh (Summit, NJ), Hege; Kristen M. (Burlingame, CA)
Assignee:	Celgene Corporation (Summit, NJ)
Application Number:	14/268,439
Patent Claims:	1. A method for treating a cancer, comprising administering an effective amount of a substituted quinazolinone compound of formula (I): ##STR00137## and pharmaceutically acceptable salts, solvates, and stereoisomers thereof, wherein: R.sup.1 is: halo; --(CH.sub.2).sub.nOH; (C.sub.1-C.sub.6)alkyl, optionally substituted with one or more halo; (C.sub.1-C.sub.6)alkoxy, optionally substituted with one or more halo; or --(CH.sub.2).sub.nNHR.sup.a, wherein R.sup.a is: hydrogen; (C.sub.1-C.sub.6)alkyl, optionally substituted with one or more halo; --(CH.sub.2).sub.n-(6 to 10 membered aryl); --C(O)--(CH.sub.2).sub.n-(6 to 10 membered aryl) or --C(O)--(CH.sub.2).sub.n-(6 to 10 membered heteroaryl), wherein the aryl or heteroaryl is optionally substituted with one or more of: halo; --SCF.sub.3; (C.sub.1-C.sub.6)alkyl, itself optionally substituted with one or more halo; or (C.sub.1-C.sub.6)alkoxy, itself optionally substituted with one or more halo; --C(O)--(C.sub.1-C.sub.8)alkyl, wherein the alkyl is optionally substituted with one or more halo; --C(O)--(CH.sub.2).sub.n-(C.sub.3-C.sub.10-cycloalkyl); --C(O)--(CH.sub.2).sub.n--NR.sup.bR.sup.c, wherein R.sup.b and R.sup.c are each independently: hydrogen; (C.sub.1-C.sub.6)alkyl, optionally substituted with one or more halo; (C.sub.1-C.sub.6)alkoxy, optionally substituted with one or more halo; or 6 to 10 membered aryl, optionally substituted with one or more of: halo; (C.sub.1-C.sub.6)alkyl, itself optionally substituted with one or more halo; or (C.sub.1-C.sub.6)alkoxy, itself optionally substituted with one or more halo; --C(O)--(CH.sub.2).sub.n--O--(C.sub.1-C.sub.6)alkyl; or --C(O)--(CH.sub.2).sub.n-(6 to 10 membered aryl); R.sup.2 is: hydrogen; --(CH.sub.2).sub.nOH; phenyl; --O--(C.sub.1-C.sub.6)alkyl; or (C.sub.1-C.sub.6 alkyl, optionally substituted with one or more halo; R.sup.3 is: hydrogen; or (C.sub.1-C.sub.6)alkyl, optionally substituted with one or more halo; and n is 0, 1, or 2; or a substituted quinazolinone compound of formula (II): ##STR00138## and pharmaceutically acceptable salts, solvates, and stereoisomers thereof, wherein: R.sup.4 is: halo; --(CH.sub.2).sub.nOH; (C.sub.1-C.sub.6)alkyl, optionally substituted with one or more halo; or (C.sub.1-C.sub.6)alkoxy, optionally substituted with one or more halo; R.sup.5 is: hydrogen; --(CH.sub.2).sub.nOH; --O--(C.sub.1-C.sub.6)alkyl, or (C.sub.1-C.sub.6)alkyl, optionally substituted with one or more halo; R.sup.6 is: hydrogen; or (C.sub.1-C.sub.6)alkyl, optionally substituted with one or more halo; and n is 0, 1, or 2; or a substituted quinazolinone compound of formula (III): ##STR00139## and pharmaceutically acceptable salts, solvates, and stereoisomers thereof, wherein: R.sup.d is: hydrogen; (C.sub.1-C.sub.6)alkyl, optionally substituted with one or more halo; --C(O)--(CH.sub.1-C.sub.8)alkyl, wherein the alkyl is optionally substituted with one or more halo; --C(O)--(CH.sub.2).sub.n--(C.sub.3-C.sub.10-cycloalkyl); --C(O)--(CH.sub.2).sub.n--NR.sup.eR.sup.f, wherein R.sup.e and R.sup.f are each independently: hydrogen; (C.sub.1-C.sub.6)alkyl, optionally substituted with one or more halo; or (C.sub.1-C.sub.6)alkoxy, optionally substituted with one or more halo; or --C(O)--(CH.sub.2).sub.n--O--(C.sub.1-C.sub.6)alkyl; R.sup.7 is: hydrogen; --(CH.sub.2).sub.nOH; phenyl; --O--(C.sub.1-C.sub.6)alkyl; or (C.sub.1-C.sub.6)or alkyl, optionally substituted with one or more halo; R.sup.8 is: hydrogen; or (C.sub.1-C.sub.6)alkyl, optionally substituted with one or more halo; and n is 0, 1, or 2 in combination with an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phen- yl)acrylamide, or a pharmaceutically acceptable salt thereof, to a patient having a cancer. 2. The method of claim 1, wherein the cancer is a blood born cancer. 3. The method of claim 2, wherein the blood born cancer is a lymphoma, a leukemia or a mutliple myeloma. 4. The method of claim 3, wherein the lymphoma is non-Hodgkin's lymphoma. 5. The method of claim 4, wherein the non-Hodgkin's lymphoma is diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), acute myeloid leukemia (AML), mantle cell lymphoma (MCL), or ALK+anaplastic large cell lymphoma. 6. The method of claim 4, wherein the non-Hodgkin's lymphoma is diffuse large B-cell lymphoma (DLBCL). 7. The method of claim 3, wherein the lymphoma is a B-cell lymphoma. 8. The method of claim 7, wherein the B-cell lymphoma is a B-cell non-Hodgkin's lymphoma selected from diffuse large B-cell lymphoma, Burkitt's lymphoma/leukemia, mantle cell lymphoma, mediastinal (thymic) large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. 9. The method of claim 8, wherein the B-cell non-Hodgkin's lymphoma is refractory B-cell non-Hodgkin's lymphoma. 10. The method of claim 8, wherein the B-cell non-Hodgkin's lymphoma is relapsed B-cell non-Hodgkin's lymphoma. 11. The method of claim 7, wherein the B-cell lymphoma is chronic lymphocytic leukemia or small lymphocytic lymphoma. 12. The method of claim 8, wherein diffuse large B-cell lymphoma is germinal center B-cell-like diffuse large B-cell lymphoma or activated B-cell-like diffuse large B-cell lymphoma. 13. The method of claim 3, wherein the lymphoma is a T-cell lymphoma. 14. The method of claim 1, wherein the cancer is a cancer of the head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, prostate, urinary bladder, uterine, cervix, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, and brain or central nervous system. 15. The method of claim 1, wherein the cancer is a cancer associated with the pathways involving mTOR, PI3K, or Akt kinases and mutants or isoforms thereof. 16. The method of claim 1, wherein the substituted quinazolinone compound is administered in combination with a besylate salt of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phen- yl)acrylamide. 17. The method of claim 1, wherein the substituted quinazolinone compound is ##STR00140## ##STR00141## ##STR00142## ##STR00143## ##STR00144## or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. 18. The method of claim 1, further comprising the administration of an anti-CD20 antibody. 19. The method of claim 18, wherein anti-CD20 antibody is rituximab. 20. The method of claim 17, wherein the substituted quinazolinone compound is: ##STR00145## or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. 21. The method of claim 20, further comprising the administration of an anti-CD20 antibody. 22. The method of claim 21, wherein anti-CD20 antibody is rituximab.

Details for Patent 9,119,854

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2033-05-03
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2033-05-03
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2033-05-03